Skip to content
DataLookout
Menu

NCT07645469

FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Oct 15, 2026 to Dec 1, 2026
  2. Notable Start date: Sep 1, 2026 to Oct 15, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Interventions: Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells (Drug), Azacitidine (Drug), Biospecimen Collection… to Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells (Drug), Azacitidine (Drug), Biospecimen Collection…
    • Study description revised
    • Site details revised
  3. Notable Eligibility criteria expanded, about 10 wordsv4
  4. Notable Start date: Aug 1, 2026 to Sep 1, 2026v3
  5. Notable Recruitment opened
    • Start date: Oct 1, 2026 to Aug 1, 2026
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of treatment related grade 3 or higher adverse events
Timeframe: From first infusion up to 1 year
Incidence of dose limiting toxicity
Timeframe: From first T cell infusion, up to 28 days

Secondary (2)

Ability to reproducibly generate and infuse T cells at the planned dose level (feasibility)
Relapse

Arms and interventions

Treatment (FH-WT1-E50 TCR T cells, azacitidine)Experimental

Patients undergo leukapheresis. 4 weeks later patients receive azacitidine IV. At least 4 weeks after the first azacitidine infusion, patients receive azacitidine IV followed by FH-WT1-E50 TCR T cells IV. If additional cells are available patients may receive a second infusion of azacitidine IV followed by FH-WT1-E50 TCR T cells IV, starting at 28 days, up to 1 year. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo MUGA scan/echocardiography and chest x-ray during screening and bone marrow biopsy and aspiration and blood sample collection throughout the study. Patients may undergo lumbar puncture on study and CT scan and/or PET scan throughout the study.

Drugs: Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine

Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Multigated Acquisition Scan, Positron Emission Tomography

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States